Switch theme
Sign up to access all valuation multiples
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
2014
63
LTM Revenue $0.7M
Last FY EBITDA -$29.0M
$14.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SAB Bio has a last 12-month revenue (LTM) of $0.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, SAB Bio achieved revenue of n/a and an EBITDA of -$29.0M.
SAB Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SAB Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$29.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$42.6M | XXX | -$42.9M | XXX | XXX | XXX |
| EBIT Margin | -5844% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$32.6M | XXX | -$34.1M | XXX | XXX | XXX |
| Net Margin | -4479% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, SAB Bio's stock price is $2.
SAB Bio has current market cap of $21.0M, and EV of $14.9M.
See SAB Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14.9M | $21.0M | XXX | XXX | XXX | XXX | $-2.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, SAB Bio has market cap of $21.0M and EV of $14.9M.
SAB Bio's trades at n/a EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate SAB Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SAB Bio has a P/E ratio of -0.6x.
See valuation multiples for SAB Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.0M | XXX | $21.0M | XXX | XXX | XXX |
| EV (current) | $14.9M | XXX | $14.9M | XXX | XXX | XXX |
| EV/Revenue | 20.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSAB Bio's last 12 month revenue growth is -35%
SAB Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.7M for the same period.
SAB Bio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SAB Bio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SAB Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -35% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SAB Bio acquired XXX companies to date.
Last acquisition by SAB Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . SAB Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SAB Bio founded? | SAB Bio was founded in 2014. |
| Where is SAB Bio headquartered? | SAB Bio is headquartered in United States of America. |
| How many employees does SAB Bio have? | As of today, SAB Bio has 63 employees. |
| Who is the CEO of SAB Bio? | SAB Bio's CEO is Mr. Samuel J. Reich. |
| Is SAB Bio publicy listed? | Yes, SAB Bio is a public company listed on NAS. |
| What is the stock symbol of SAB Bio? | SAB Bio trades under SABS ticker. |
| When did SAB Bio go public? | SAB Bio went public in 2021. |
| Who are competitors of SAB Bio? | Similar companies to SAB Bio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of SAB Bio? | SAB Bio's current market cap is $21.0M |
| What is the current revenue of SAB Bio? | SAB Bio's last 12 months revenue is $0.7M. |
| What is the current revenue growth of SAB Bio? | SAB Bio revenue growth (NTM/LTM) is -35%. |
| What is the current EV/Revenue multiple of SAB Bio? | Current revenue multiple of SAB Bio is 20.5x. |
| Is SAB Bio profitable? | Yes, SAB Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
